Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wanjun Lu

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Therapeutic Advances in Medical Oncology|July 6, 2026
CD39+CD8+ T cell infiltration is associated with clinical outcomes of subsequent immunotherapy in advanced EGFR-mutant non-small cell lung cancerWanjun Lu, Qiuxia Wu, Zimu Wang, et al.
International Immunopharmacology|June 20, 2024
A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancerXueying Zuo, Qinpei Cheng, Zimu Wang, et al.
International Immunopharmacology|August 16, 2024
Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapyYuxin Jiang, Jingyuan Xie, Qinpei Cheng, et al.
Therapeutic Advances in Medical Oncology|February 29, 2024
Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysisJiayan Chen, Wanjun Lu, Mo Chen, et al.
Translational Lung Cancer Research|January 20, 2025
Radiomicsmetabolic signature profiles for advanced non-small cell lung cancer with chemoimmunotherapy by reflecting biological function and survivalYuxin Jiang, Tao Liu, Ke Xu, et al.
Respiratory Research|May 10, 2025
Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusionQinpei Cheng, Xueying Zuo, Zimu Wang, et al.
Translational Lung Cancer Research|October 21, 2024
Lymph nodes rather than pleural metabolic activity in <sup>18</sup>F-FDG PET/CT correlates with malignant pleural effusion recurrence in advanced non-small cell lung cancerYuxin Jiang, Tao Liu, Ke Xu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|July 24, 2023
[Effect of Different Antitumor Regimens on Incidence and Severity of Corona Virus 
Disease 2019 Pneumonia in Lung Cancer Patients: 
A Single-center Retrospective Study]Wanjun Lu, Jiawen Lv, Qin Wang, et al.
Translational Lung Cancer Research|July 11, 2026
Impact of chronic obstructive pulmonary disease on the prognosis of patients with extensive-stage small-cell lung cancer treated with chemoimmunotherapyYuxin Jiang, Yu Li, Yanjun Du, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2024
A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patientsYuxin Jiang, Yueying Chen, Qinpei Cheng, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Therapeutic Advances in Medical Oncology|July 6, 2026
CD39+CD8+ T cell infiltration is associated with clinical outcomes of subsequent immunotherapy in advanced EGFR-mutant non-small cell lung cancerWanjun Lu, Qiuxia Wu, Zimu Wang, et al.
International Immunopharmacology|June 20, 2024
A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancerXueying Zuo, Qinpei Cheng, Zimu Wang, et al.
International Immunopharmacology|August 16, 2024
Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapyYuxin Jiang, Jingyuan Xie, Qinpei Cheng, et al.
Therapeutic Advances in Medical Oncology|February 29, 2024
Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysisJiayan Chen, Wanjun Lu, Mo Chen, et al.
Translational Lung Cancer Research|January 20, 2025
Radiomicsmetabolic signature profiles for advanced non-small cell lung cancer with chemoimmunotherapy by reflecting biological function and survivalYuxin Jiang, Tao Liu, Ke Xu, et al.
Respiratory Research|May 10, 2025
Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusionQinpei Cheng, Xueying Zuo, Zimu Wang, et al.
Translational Lung Cancer Research|October 21, 2024
Lymph nodes rather than pleural metabolic activity in <sup>18</sup>F-FDG PET/CT correlates with malignant pleural effusion recurrence in advanced non-small cell lung cancerYuxin Jiang, Tao Liu, Ke Xu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|July 24, 2023
[Effect of Different Antitumor Regimens on Incidence and Severity of Corona Virus 
Disease 2019 Pneumonia in Lung Cancer Patients: 
A Single-center Retrospective Study]Wanjun Lu, Jiawen Lv, Qin Wang, et al.
Translational Lung Cancer Research|July 11, 2026
Impact of chronic obstructive pulmonary disease on the prognosis of patients with extensive-stage small-cell lung cancer treated with chemoimmunotherapyYuxin Jiang, Yu Li, Yanjun Du, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2024
A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patientsYuxin Jiang, Yueying Chen, Qinpei Cheng, et al.
Pageof 4